ImmunityBio (NASDAQ:IBRX) reported quarterly earnings results on February 23, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.06, beating the consensus estimate of $-0.09 by $0.03 per share. Revenue came in at $38.3M, beating the estimate of $37.5M.
ImmunityBio's stock moved following the earnings release. The stock currently trades at $10.44 with a market capitalization of $2.2B.